Lymphoma cell clearance

Lymphoma cell clearance refers to the biological process or therapeutic objective of eliminating malignant lymphocytes from the blood, bone marrow, and lymphatic system. It is important to note that 'Lymphoma cell clearance' is not a specific molecular target (such as a receptor or enzyme), but rather a clinical result or physiological mechanism mediated by the immune system or medical intervention (NCI Dictionary, 2023). This process is typically achieved using monoclonal antibodies or CAR-T cell therapies that target specific surface antigens like CD20, CD19, or CD30 to trigger immune-mediated destruction (PubMed: 33024561). Mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated lysis play central roles in facilitating this clearance (StatPearls: NBK545245). In clinical settings, the efficiency of clearance is a critical measure of treatment efficacy and is often monitored through minimal residual disease (MRD) assays to predict the likelihood of relapse (NIH: PMC7513364). Consequently, while clearance is the goal of lymphoma therapy, the actual 'targets' are the specific proteins expressed by the cancer cells that allow these clearing mechanisms to occur.

Other names

Malignant B-cell depletionTumor cell clearanceLymphoma eradicationB-cell clearance

Lymphoma cell clearance is a therapeutic outcome achieved through various immunological and pharmacological mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and the direct induction of apoptosis via targeted therapy (PubMed: 25161012; StatPearls: NBK557398).